Advertisement
YOU ARE HERE: LAT HomeCollectionsSchering Ag
IN THE NEWS

Schering Ag

FEATURED ARTICLES
BUSINESS
November 3, 1988 | JOHN O'DELL, Times Staff Writer
ICN Pharmaceuticals, which earlier this year made an unsuccessful run at Swiss drug giant F. Hoffman-La Roche, has reportedly notified the Federal Trade Commission that it intends to acquire up to 25% of the stock of West German pharmaceutical house Schering AG. Schering AG, according to a Dow Jones report Wednesday, was told of ICN's intentions by the FTC and immediately branded the bid an "unwelcome . . . hostile . . . greenmail" attempt.
ARTICLES BY DATE
BUSINESS
December 27, 2001 | Reuters
Schering-Plough Corp. said it will charge 18% less for its new allergy drug Clarinex than for its blockbuster Claritin, in a bid to switch patients to Clarinex before the older drug loses its U.S. marketing exclusivity late next year. The Food and Drug Administration last week approved Clarinex, a slightly altered form of Claritin, for use in treating seasonal allergies. Schering-Plough said Friday that it plans to launch the treatment in January, but had not disclosed how it would be priced.
Advertisement
BUSINESS
July 4, 1998 | Associated Press
The Brazilian government suspended sales of all products made by German pharmaceutical giant Schering's local subsidiary, whose phony birth control pills are blamed for several unwanted pregnancies. The suspension by the Health Ministry came two days after Schering was slapped with a $2.5-million fine, following reports by at least 10 women that they became pregnant after taking fake Microvlar contraceptives manufactured by Schering.
NEWS
December 27, 1997
W.H. Conzen, 84, the former chief executive of drug maker Schering-Plough Corp. and the driving force behind the merger that created the company. Conzen began working in the pharmaceutical industry, at the Schering AG company, in his native Germany in 1931. He was named general manager after transferring to a subsidiary, Scherag Ltd., in South Africa during World War II. He later moved to the United States and became president of Schering.
CALIFORNIA | LOCAL
February 4, 1991 | From Times Staff and Wire Reports
Animal studies may have uncovered a new route for developing drugs to slow or halt the debilitating progression of Parkinson's disease, researchers from the German drug company Schering AG reported last week. The researchers said in the journal Nature that they have found drugs that block the so-called NMDA receptors on the surface of rat brain cells and thereby protect the cells from the harmful effects of a chemical known to cause symptoms like Parkinson's.
BUSINESS
September 22, 1990 | LINDA DARNELL WILLIAMS, TIMES STAFF WRITER
Triton Biosciences Inc. said Friday that its pharmaceuticals business will be sold to Schering AG, a Berlin-based pharmaceuticals company with worldwide marketing that is trying to increase its presence in biotechnology. Alameda-based Triton, a unit of Houston-based Shell Oil Co., is not strictly a biotechnology company, but much of its research and development is based on biotechnology.
BUSINESS
December 27, 2001 | Reuters
Schering-Plough Corp. said it will charge 18% less for its new allergy drug Clarinex than for its blockbuster Claritin, in a bid to switch patients to Clarinex before the older drug loses its U.S. marketing exclusivity late next year. The Food and Drug Administration last week approved Clarinex, a slightly altered form of Claritin, for use in treating seasonal allergies. Schering-Plough said Friday that it plans to launch the treatment in January, but had not disclosed how it would be priced.
BUSINESS
July 4, 1998 | Associated Press
The Brazilian government suspended sales of all products made by German pharmaceutical giant Schering's local subsidiary, whose phony birth control pills are blamed for several unwanted pregnancies. The suspension by the Health Ministry came two days after Schering was slapped with a $2.5-million fine, following reports by at least 10 women that they became pregnant after taking fake Microvlar contraceptives manufactured by Schering.
BUSINESS
August 24, 1995 | Times Staff and Wire Reports
Schering Agrees to Buy U.S. Firm: The German drug maker said it agreed to acquire Medrad Inc., a Pennsylvania maker of vascular injection systems used in medical imaging, for about $180 million, or $28 a share. Last spring, Medrad retained Dillon Read & Co. and Parker Hunter Inc. to explore strategic options that included making acquisitions or selling the company. Medrad shares closed up $5.375 at $27.625 in Nasdaq trading.
NEWS
December 27, 1997
W.H. Conzen, 84, the former chief executive of drug maker Schering-Plough Corp. and the driving force behind the merger that created the company. Conzen began working in the pharmaceutical industry, at the Schering AG company, in his native Germany in 1931. He was named general manager after transferring to a subsidiary, Scherag Ltd., in South Africa during World War II. He later moved to the United States and became president of Schering.
BUSINESS
August 24, 1995 | Times Staff and Wire Reports
Schering Agrees to Buy U.S. Firm: The German drug maker said it agreed to acquire Medrad Inc., a Pennsylvania maker of vascular injection systems used in medical imaging, for about $180 million, or $28 a share. Last spring, Medrad retained Dillon Read & Co. and Parker Hunter Inc. to explore strategic options that included making acquisitions or selling the company. Medrad shares closed up $5.375 at $27.625 in Nasdaq trading.
CALIFORNIA | LOCAL
February 4, 1991 | From Times Staff and Wire Reports
Animal studies may have uncovered a new route for developing drugs to slow or halt the debilitating progression of Parkinson's disease, researchers from the German drug company Schering AG reported last week. The researchers said in the journal Nature that they have found drugs that block the so-called NMDA receptors on the surface of rat brain cells and thereby protect the cells from the harmful effects of a chemical known to cause symptoms like Parkinson's.
BUSINESS
September 22, 1990 | LINDA DARNELL WILLIAMS, TIMES STAFF WRITER
Triton Biosciences Inc. said Friday that its pharmaceuticals business will be sold to Schering AG, a Berlin-based pharmaceuticals company with worldwide marketing that is trying to increase its presence in biotechnology. Alameda-based Triton, a unit of Houston-based Shell Oil Co., is not strictly a biotechnology company, but much of its research and development is based on biotechnology.
BUSINESS
November 3, 1988 | JOHN O'DELL, Times Staff Writer
ICN Pharmaceuticals, which earlier this year made an unsuccessful run at Swiss drug giant F. Hoffman-La Roche, has reportedly notified the Federal Trade Commission that it intends to acquire up to 25% of the stock of West German pharmaceutical house Schering AG. Schering AG, according to a Dow Jones report Wednesday, was told of ICN's intentions by the FTC and immediately branded the bid an "unwelcome . . . hostile . . . greenmail" attempt.
BUSINESS
March 20, 2001 | Dow Jones
Biomerica Inc., a Newport Beach medical technology company, said Monday it will market its 10-minute prostate cancer test to hospitals and physicians in Japan through Nihon Schering, a unit of Schering AG. Financial terms were not disclosed. Biomerica said last week that Japanese regulators approved the sale of its EZ-PSA test, which detects elevated levels of prostate-specific antigen, an early warning indicator of prostate cancer.
Los Angeles Times Articles
|